Galmed Pharmaceuticals Ltd. (GLMD)
GLMD Stock Price Chart
Explore Galmed Pharmaceuticals Ltd. interactive price chart. Choose custom timeframes to analyze GLMD price movements and trends.
GLMD Company Profile
Discover essential business fundamentals and corporate details for Galmed Pharmaceuticals Ltd. (GLMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Mar 2014
Employees
5.00
Website
https://galmedpharma.comCEO
Allen Baharaff
Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
GLMD Financial Timeline
Browse a chronological timeline of Galmed Pharmaceuticals Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.39.
Earnings released on 8 Jul 2026
EPS came in at -$0.29 surpassing the estimated -$0.38 by +23.68%.
Earnings released on 26 Nov 2025
EPS came in at -$0.33 surpassing the estimated -$0.54 by +38.89%.
Earnings released on 28 Aug 2025
EPS came in at $0.63 surpassing the estimated -$0.83 by +175.90%.
Earnings released on 22 May 2025
EPS came in at -$0.62 surpassing the estimated -$0.89 by +30.34%.
Earnings released on 2 Apr 2025
EPS came in at -$1.94 falling short of the estimated -$0.89 by -117.98%, while revenue for the quarter reached $1.64m , beating expectations by +6.55%.
Earnings released on 14 Nov 2024
EPS came in at -$2.31 .
Stock split effective on 30 Aug 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Aug 2024
EPS came in at $2.16 .
Earnings released on 30 May 2024
EPS came in at -$0.23 .
Earnings released on 4 Apr 2024
EPS came in at -$0.98 falling short of the estimated -$0.32 by -206.25%.
Earnings released on 22 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.32 by +25.00%.
Earnings released on 9 Aug 2023
EPS came in at -$0.95 falling short of the estimated -$0.34 by -179.41%.
Earnings released on 1 Jun 2023
EPS came in at -$13.09 falling short of the estimated -$1.50 by -772.67%.
Stock split effective on 15 May 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Mar 2023
EPS came in at -$18.00 surpassing the estimated -$25.20 by +28.57%.
Earnings released on 16 Nov 2022
EPS came in at -$0.21 falling short of the estimated -$0.16 by -31.25%.
Earnings released on 4 Aug 2022
EPS came in at -$27.00 surpassing the estimated -$41.40 by +34.78%.
Earnings released on 17 May 2022
EPS came in at -$43.20 surpassing the estimated -$59.39 by +27.26%.
Earnings released on 8 Nov 2021
EPS came in at -$55.79 surpassing the estimated -$71.99 by +22.50%.
Earnings released on 5 Aug 2021
EPS came in at -$59.39 surpassing the estimated -$73.79 by +19.51%.
GLMD Stock Performance
Access detailed GLMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
